Vicore Pharma Holding AB (publ) (VICO) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.074x

Based on the latest financial reports, Vicore Pharma Holding AB (publ) (VICO) has a cash flow conversion efficiency ratio of -0.074x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-81.48 Million ≈ $-8.77 Million USD) by net assets (Skr1.10 Billion ≈ $117.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Vicore Pharma Holding AB (publ) to measure how much of total assets are equity-financed.

Vicore Pharma Holding AB (publ) - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Vicore Pharma Holding AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Vicore Pharma Holding AB (publ) to evaluate the quality of earnings relative to operating cash generation.

Vicore Pharma Holding AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Vicore Pharma Holding AB (publ) ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Shifeng Cultural Development Co Ltd SHE:002862	0.031x
Taeyoung Engineering & Construction Co.,Ltd. KO:009410	-0.073x
Qibu Co Ltd SHG:603557	-0.263x
Clinuvel Pharmaceuticals Ltd AU:CUV	0.050x
Shoper S.A. WAR:SHO	0.225x
Beijing E-techstar Co Ltd SHE:300513	-0.096x
CHECKPOINT THER. DL-0001 F:CZTA	N/A
Xinjiang Sayram Modern Agriculture Co Ltd SHG:600540	-1.899x

Annual Cash Flow Conversion Efficiency for Vicore Pharma Holding AB (publ) (2012–2025)

The table below shows the annual cash flow conversion efficiency of Vicore Pharma Holding AB (publ) from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Vicore Pharma Holding AB (publ) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr1.10 Billion ≈ $117.89 Million	Skr-374.44 Million ≈ $-40.30 Million	-0.342x	-134.02%
2024-12-31	Skr1.13 Billion ≈ $121.53 Million	Skr-164.95 Million ≈ $-17.75 Million	-0.146x	+73.35%
2023-12-31	Skr455.39 Million ≈ $49.01 Million	Skr-249.58 Million ≈ $-26.86 Million	-0.548x	+47.17%
2022-12-31	Skr289.08 Million ≈ $31.11 Million	Skr-299.92 Million ≈ $-32.28 Million	-1.037x	-49.97%
2021-12-31	Skr383.32 Million ≈ $41.25 Million	Skr-265.17 Million ≈ $-28.54 Million	-0.692x	-104.48%
2020-12-31	Skr354.51 Million ≈ $38.15 Million	Skr-119.94 Million ≈ $-12.91 Million	-0.338x	-25.06%
2019-12-31	Skr321.60 Million ≈ $34.61 Million	Skr-87.00 Million ≈ $-9.36 Million	-0.271x	-133.73%
2018-12-31	Skr285.44 Million ≈ $30.72 Million	Skr-33.04 Million ≈ $-3.56 Million	-0.116x	-69.69%
2017-12-31	Skr112.97 Million ≈ $12.16 Million	Skr-7.71 Million ≈ $-829.18K	-0.068x	+28.89%
2016-12-31	Skr75.60 Million ≈ $8.14 Million	Skr-7.25 Million ≈ $-780.32K	-0.096x	-113.43%
2015-12-31	Skr81.93 Million ≈ $8.82 Million	Skr-3.68 Million ≈ $-396.24K	-0.045x	+14.58%
2014-12-31	Skr53.70 Million ≈ $5.78 Million	Skr-2.83 Million ≈ $-304.02K	-0.053x	-17.40%
2013-12-31	Skr40.01 Million ≈ $4.31 Million	Skr-1.79 Million ≈ $-192.96K	-0.045x	+29.52%
2012-12-31	Skr26.25K ≈ $2.82K	Skr-1.67K ≈ $-179.61	-0.064x	--

About Vicore Pharma Holding AB (publ)

ST:VICO Sweden Biotechnology

Market Cap

$325.99 Million

Skr3.03 Billion SEK

Market Cap Rank

#14307 Global

#239 in Sweden

Share Price

Skr10.76

Change (1 day)

-3.24%

52-Week Range

Skr9.47 - Skr15.68

All Time High

Skr37.60